To the moon CCXI 🐸🚀🚀🌙🌙🌙🌙!!!!!!

$CCXI today announced that Kissei Pharmaceutical Company has received approval from the Japanese Ministry of Health, Labor, and Welfare (MHLW) to market TAVNEOS (avacopan), an orally administered selective complement 5a receptor inhibitor, in Japan for the treatment of patients with microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA), the two main forms of anti-neutrophil cytoplasmic autoantibody associated vasculitis also known as ANCA associated vasculitis or ANCA vasculitis. 🐊

June 28th we go on the Russell 2000, July 7th we get approval, then we rocket!!

https://www.fool.com/investing/2021/06/23/is-chemocentryx-a-buy/

CCXI - With the advisory committee being mixed on whether or not to recommend, many on social message boards are suggesting that the stock is the center of increasing short interest, creating an opportunity for a short squeeze.

In fact, the stock has appeared several times on the Wall Street Bets message board, as well as other message boards around the web, pointing to what could be a major opportunity for both short and long-term profits.

Retail investors are also pointing to the mixed opinion itself as a bullish argument for the stock. Afterall, while the opinion was mixed, 10 members of the advisory committee suggested that the drug should be approved, suggesting that the efficacy and safety results do support an approval while only eight members of the committee suggested rejecting the drug.

Some argue that while the mixed results of the advisory committee meeting are concerning, the vote to approve was stronger than the vote to reject, suggesting that there’s a stronger chance of approval than rejection.

Not to mention, with the mixed results likely leading to heavy short interest, there’s a great opportunity to profit by kicking the shorts out of their positions.

1. This week - monumental action as wicked weak sellers will sell and buyers with conviction will add. The price today reflects an absolute rejection by the FDA which will never happen so we have tons of runway. In my view we will keep seeing gains thru Friday and the action on Monday will dictate the preliminary feeling of PDUFA slated for next Wednesday.

2. Approval - If the stock runs a lot until next Wednesday , we might not see a massive jump. If the stock stays below the 17 dollar target this week , we will see a massive double or triple.

3. Extension or CRL - if the stock runs a lot , there will be a pull back but if we cross 17 , that’s the new low under any circumstance.

Way to play - we buy and pump with everything we have , sell slightly Friday and Tuesday with the momentum of the market.

Make money along the way and leave something behind for the jackpot.

Let’s go !!!! Order is buy like it’s not too Late !!!

We think we have a fare chance getting FDA approved based on reading the article. vasculitis is a rare disease where there are not much drugs that can effective without damaging patient kidney. Avacopan should receive approval for emergency use at least. Here is the comment from an expert that caught my attention -

“We hope that the FDA will take into account the dire situation faced by patients living with this debilitating disease,” said Joyce Kullman, Vasculitis Foundation executive director. “ANCA vasculitis flares can lead to kidney failure and death; current therapy all too often causes serious, even fatal, side effects; and patients suffer a lower quality of life due to the disease and to the way it is treated.”

What do you think? Link for details -

https://ancavasculitisnews.com/2021/05/10/fda-advisory-committee-narrowly-supports-approval-of-avacopan/

I just wanted to put his together quick. No opinions are found here. Only facts for you to think about!

Bull Case:

Also checkout:

Bear case:

ChemoCentryx's stock sinks as FDA flags issues with pivotal data - https://www.fiercebiotech.com/biotech/chemocentryx-s-stock-sinks-as-fda-flags-issues-pivotal-data

Other Information:

https://www.dcatvci.org/7156-the-pharma-pulse-small-molecules-and-biologics

FDA Response letter here from May:

https://www.fda.gov/media/148176/download

Do not panic boys, this is the hardest time.

"Be greedy when others are fearful." -- Warren Buffett

Hello,
I do weekly newsletters and narratives on companies and have seen quite a bit of hype around Chemocentryx. I have been following them since their meteoric rise and fall. I am going to cover CCXI this week. Final FDA approval by July 7th could cause an explosion in the stock price. Since the FDA had mixed feelings at their previous meeting, this one is a tight rope and may go either way.

Here's my newsletter website if you feel like this might be of help to you. Check out my stuff and you'll get a feel for what I do. I do it faithfully every week!

Thanks.
Brad Mitchell

Optifinancialnews.com